NEWS & EVENTS

Patient-Derived Tissue Therapies Gaining Practitioners

Greystone Associates Identifies Process and Outcome Improvements as Key Market Drivers

(Amherst, NH) – The ability to isolate, purify and re-inject patient-derived cells with regenerative properties has led to a number of therapeutic products for the treatment of refractory injuries and wounds. Autologous therapies are having an impact on a number of areas, including cardiovascular medicine, refractory wound care, orthopedics, and surgical medicine.

Applications for patient-derived tissue repair are expanding beyond traditional refractory wound care markets to encompass a growing list of surgical procedures and orthopedic restoration applications. The market for autologous tissue repair will continue to grow at an increasing rate due to favorable demographics. More than two-dozen autologous tissue repair products are currently being marketed or are in development, several with the potential to have a significant impact on regenerative medicine.

The potential economic benefits of autologous treatments are significant, as an aging population struggles with intractable ailments that historically have required numerous follow-up provider visits. While several approved autologous products require remote processing, the number of autologous therapeutics that can be processed at the point-of-care is increasing. Twenty-seven separate companies worldwide have products and development programs for autologous tissue repair – companies working to shape the future of tissue regeneration.